Synthesis and preliminary evaluation of [11C]KF17837, a selective adenosine A2A antagonist
β Scribed by Kiichi Ishiwata; Junko Noguchi; Hinako Toyama; Yojiro Sakiyama; Nobuaki Koike; Shin-Ichi Ishii; Keiichi Oda; Kazutoyo Endo; Fumio Suzuki; Michio Senda
- Publisher
- Elsevier Science
- Year
- 1996
- Tongue
- English
- Weight
- 371 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0969-8043
No coin nor oath required. For personal study only.
β¦ Synopsis
An 11C-labeled selective adenosine A2A antagonist, (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-[11C]-methylxanthine ([11C]KF17837), was prepared by reaction of (E)-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine and [11C]methyl iodide with decay-corrected radiochemical yield of 19-50%, radiochemical purity of > 99%, sp. act. of 17-100 GBq/mumol and preparation time of 20-25 min. In mice, the myocardium showed the highest (13.4% ID/g) at 5 min after i.v. injection, which decreased gradually with time. The specific myocardial uptake was visualized by gamma-camera. In the brain region the radioactivity level was higher in the A2A receptors-rich striatum than in the cortex and cerebellum. The specific striatal uptake in rats was clearly demonstrated by PET. These results have shown that [11C]KF17837 is a potential PET radioligand for mapping the adenosine A2A receptors in the heart and brain.
π SIMILAR VOLUMES
## Abstract We demonstrated the synthesis of carbonβ11 labeled 17β__Ξ±__βhydroxyβ11β__Ξ²__β/4β/[methyl]β[1βmethylethyl]βaminophenyl/β17__Ξ±__β[propβ1βynyl]estaβ4β9βdieneβ3βone (RU40555), a selective glucocorticoid receptor (GR) antagonist, and examined the __in vivo__ profile of [^11^C]RU40555. [^11^
Movement disorders such as Parkinson's disease and Huntington's disease are serious life-limiting and debilitating movement disorders. Their onset typically occurs from mid-life to late in life, and effective diagnostic techniques for detecting and following the disease course are lacking. Our goal